Reata Pharmaceuticals Equity 2024

Reata Pharmaceuticals Aktienanalyse

What does Reata Pharmaceuticals do?

Reata Pharmaceuticals Inc is a biopharmaceutical company that was founded in Irving, Texas in 2002. The company develops and markets innovative therapeutics for severe and rare diseases, particularly rare genetic metabolic diseases, neurological diseases, and inflammatory diseases. Reata Pharmaceuticals has a unique business model based on the principle of "platform technology". This means that the company develops various therapeutic approaches based on a patented molecular platform. This platform allows Reata to quickly and efficiently develop new products for different disease areas. An important focus of Reata Pharmaceuticals' activities is the development of therapeutics for rare genetic metabolic diseases. The company has made remarkable progress in this area. In particular, the drug Omaveloxolone, which was developed for the treatment of Friedreich's ataxia, has attracted a lot of attention. This rare disease manifests as progressive spastic paralysis and can eventually lead to death. The drug has shown promising results in a Phase 2 study and is currently in Phase 3 study. Another important area for Reata Pharmaceuticals is inflammatory diseases. The company has developed a product called Bardoxolone Methyl, which is approved for the treatment of chronic kidney disease and pulmonary hypertension. These diseases have a significant impact on the quality of life and life expectancy of patients. Bardoxolone Methyl has shown in clinical studies that it can slow disease progression and significantly improve symptoms. In addition to these two pillars of activity, Reata Pharmaceuticals also has various product candidates for neurological diseases, cancer, and other diseases in the pipeline. The company aims to develop innovative solutions for unmet medical needs and help patients whose needs have not been adequately addressed. The history of Reata Pharmaceuticals is characterized by a successful path as a company with a unique business model. The company aims to play a leading role in the development and marketing of therapeutics for rare and serious diseases. To achieve this, the company has built a strong research and development team and works closely with the academic community. Reata Pharmaceuticals has managed to establish an international network of leading scientists, doctors, and patient organizations. This collaboration is crucial for the successful development and marketing of therapeutics for rare diseases. In summary, Reata Pharmaceuticals Inc is an innovative biopharmaceutical company that uses a unique platform technology for the development of therapeutics for rare and severe diseases. The company has made remarkable progress in the development of therapeutics for rare genetic metabolic diseases and inflammatory diseases and is working on additional products for neurological diseases, cancer, and other diseases. Reata Pharmaceuticals aims to play a leading role in the industry and help patients whose needs have not been adequately addressed. Reata Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Reata Pharmaceuticals's Equity

Reata Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Reata Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Reata Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Reata Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Reata Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Reata Pharmaceuticals Stock

What is the equity of Reata Pharmaceuticals this year?

Reata Pharmaceuticals has equity of -65.69 M USD this year.

What was the equity of Reata Pharmaceuticals compared to the previous year?

The equity of Reata Pharmaceuticals has increased/decreased by -135.32% decreased compared to the previous year.

What impact does a high equity have on investors of Reata Pharmaceuticals?

A high equity is advantageous for investors of Reata Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Reata Pharmaceuticals?

A low equity can be a risk for investors of Reata Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Reata Pharmaceuticals affect the company?

An increase in equity of Reata Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Reata Pharmaceuticals affect the company?

A reduction in equity of Reata Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Reata Pharmaceuticals?

Some factors that can affect the equity of Reata Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Reata Pharmaceuticals so important for investors?

The equity of Reata Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Reata Pharmaceuticals take to change the equity?

To change equity, Reata Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Reata Pharmaceuticals pay?

Over the past 12 months, Reata Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Reata Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Reata Pharmaceuticals?

The current dividend yield of Reata Pharmaceuticals is .

When does Reata Pharmaceuticals pay dividends?

Reata Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Reata Pharmaceuticals?

Reata Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Reata Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Reata Pharmaceuticals located?

Reata Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Reata Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Reata Pharmaceuticals from 5/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/27/2024.

When did Reata Pharmaceuticals pay the last dividend?

The last dividend was paid out on 5/27/2024.

What was the dividend of Reata Pharmaceuticals in the year 2023?

In the year 2023, Reata Pharmaceuticals distributed 0 USD as dividends.

In which currency does Reata Pharmaceuticals pay out the dividend?

The dividends of Reata Pharmaceuticals are distributed in USD.